AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 181 min read$SKYE

5AM Partners VII, LLC (DIEKMAN JOHN D, PARMAR KUSH) sold $65K of SKYE (indirect holdings)

5AM Partners VII, LLC sold 33,892 indirectly-held shares of Skye Bioscience, Inc. (SKYE) at $1.91 across 2 trades on 2026-09-16. Filed jointly with 5AM Ventures VII, L.P. (10% owner), 5AM Partners II, LLC (10% owner), 5AM Ventures II LP (10% owner), 5AM CO-INVESTORS II LP (10% owner), DIEKMAN JOHN D (10% owner), PARMAR KUSH (10% owner) and ROCKLAGE SCOTT M (10% owner).

Original reporting
SEC EDGAR · 5AM Partners VII, LLC, 5AM Ventures VII, L.P., 5AM Partners II, LLC, 5AM Ventures II LP, 5AM CO-INVESTORS II LP, DIEKMAN JOHN D, PARMAR KUSH, ROCKLAGE SCOTT M
Published Sep 18, 2026, 10:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 10:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$SKYE
Neutral
high confidence
Mentioned
$SKYE
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SKYENeutralLow
01

Why it matters

Provides fresh, primary‑source data on insider activity; limited trading relevance.

02

Market read

Small insider sell; unlikely to affect broader market.

03

What to watch

Potential upcoming financing or dilution events not disclosed.

Relevance 3/10Novelty 4/10Timing: post‑market 2026‑09‑16

Background

Form 4 filing by a 10% owner of Skye Bioscience detailing an open‑market sale.

Company-level read

Ticker impact

$SKYENeutralHigh confidence
Context

5AM Partners VII sold 33,892 shares of Skye Bioscience for $64,734, reducing its stake to 5,616 shares.

Expected impact

minimal impact, possible slight downward pressure

Evidence & confidence

The transaction size (~$65k) is small relative to market cap; insider is a 10% owner but sale is modest and disclosed via Form 4, the first report.

Market effects

Sector

Limited effect on biotech sector; typical insider sell signals no major upcoming news.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

  • Company
    Skye Bioscience, Inc.

    Biotech firm listed on NASDAQ under SKYE.

  • Investor
    5AM Partners VII, LLC

    Insider holder selling shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SKYE insider trading history →

Related articles

AUG 17
$SKYEMedAI 8/10

Skye To Acquire Redx; $125M Financing Secures Path To RXC008 Phase 2 Trial; Stock Up

Skye Bioscience (SKYE) will acquire Redx Pharma via a scheme of arrangement, creating Nasdaq-listed Fibrx Therapeutics led by Redx management. The lead asset is RXC008 for fibrostenotic Crohn’s, with FDA Fast Track and Phase 2 topline data expected in H2 2028. Financing totals $125M, including a $68M PIPE and $36M Series A, funding operations into 2029. SKYE closed at $0.50.

rttnews.com4 min
AUG 14
$SKYEHighAI 9/10

Skye Bioscience, Inc.: Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings

Skye Bioscience (Nasdaq: SKYE) will acquire privately held Redx Pharma via a UK scheme of arrangement, forming Fibrx Therapeutics that will trade on Nasdaq. The deal includes about $125 million in committed financings, including a ~$68 million PIPE and a $36 million Series A. Funds are expected to support RXC008 Phase 2 through 2029, with topline data in H2 2028.

finanznachrichten.de4 min
OCT 23
$RENTMed

Nexus Capital Management LP (Cohen Michael S, Flesh Daniel E.) purchased $2.2M of RENT (indirect holdings)

Nexus Capital Management LP purchased 632,922 indirectly-held shares of Rent the Runway, Inc. (RENT) at $3.55 ($2.25M total) on 2026-10-21. Filed jointly with Gateway Runway, LLC (Director), Gateway Runway Intermediate Holdings, Inc. (Director), NEXUS SPECIAL SITUATIONS III, L.P. (Director), NEXUS SPECIAL SITUATIONS III (CAYMAN), L.P. (Director), Nexus Special Situations GP III, LP (Director), Nexus Partners III, LLC (Director), Cohen Michael S (Director), Flesh Daniel E. (Director) and Giangiacomo Damian (Director).

SEC EDGAR1 min